1	Accuracy of digital chest x-ray analysis with artificial intelligence software as a triage and screening
2	tool in hospitalized patients being evaluated for tuberculosis in Lima, Peru.
3	
4	Amanda Biewer ^{1*} , Christine Tzelios ^{2*} , Karen Tintaya ³ , Betsabe Roman ³ , Shelley Hurwitz ² , Courtney M.
5	Yuen ⁴ , Carole D. Mitnick ⁴ , Edward Nardell ⁴ , Leonid Lecca ³ , Dylan B. Tierney ^{4,5} , Ruvandhi R.
6	Nathavitharana ^{1#}
7 8 9 10 11 12 13 14	 ¹ Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA ² Harvard Medical School, Boston, MA ³ Socios en Salud, Lima, Peru ⁴ Brigham and Women's Hospital and Harvard Medical School, Boston, MA ⁵ Massachusetts Department of Public Health, Boston, MA * contributed equally # corresponding author
15	
16	
17	Abstract
18	Introduction:
19	Tuberculosis (TB) transmission in healthcare facilities is common in high-incidence countries. Yet, the
20	optimal approach for identifying inpatients who may have TB is unclear. We evaluated the diagnostic
21	accuracy of qXR (Qure.ai, India) computer-aided detection (CAD) software versions 3.0 and 4.0 (v3
22	and v4) as a triage and screening tool within the FAST (Find cases Actively, Separate safely, and Treat
23	effectively) transmission control strategy.
24	
25	Methods:
26	We prospectively enrolled two cohorts of patients admitted to a tertiary hospital in Lima, Peru: one
27	group had cough or TB risk factors (triage) and the other did not report cough or TB risk factors
28	(screening). We evaluated the sensitivity and specificity of qXR for the diagnosis of pulmonary TB

- using culture and Xpert as primary and secondary reference standards, including stratified analyses
 based on risk factors.
- 31
- 32 Results:
- In the triage cohort (n=387), qXR v4 sensitivity was 0.91 (59/65, 95% CI 0.81-0.97) and specificity was
- 34 0.32 (103/322, 95% CI 0.27-0.37) using culture as reference standard. There was no difference in the
- 35 area under the receiver-operating-characteristic curve (AUC) between qXR v3 and qXR v4 with either
- 36 a culture or Xpert reference standard. In the screening cohort (n=191), only one patient had a
- 37 positive Xpert result, but specificity in this cohort was high (>90%). A high prevalence of radiographic
- 38 lung abnormalities, most notably opacities (81%), consolidation (62%), or nodules (58%), was
- 39 detected by qXR on digital CXR images from the triage cohort.
- 40
- 41 Conclusions:
- 42 qXR had high sensitivity but low specificity as a triage in hospitalized patients with cough or TB risk
- 43 factors. Screening patients without cough or risk factors in this setting had a low diagnostic yield.
- 44 These findings further support the need for population and setting-specific thresholds for CAD
- 45 programs.
- 46
- 47
- 48
- 49
- 50
- 51

52 Introduction

53	Diagnosis remains the largest gap in the tuberculosis (TB) cascade of care. In 2021, of the 10.6 million
54	people estimated to become sick due to TB, only 6.4 million were diagnosed and notified to national
55	notification systems(1). Efforts to increase and accelerate diagnoses are critical to prevent severe
56	disease, avert TB deaths, and halt ongoing transmission(2). Healthcare facilities are known hotspots
57	for TB transmission in high-incidence settings(3–7). Globally, the rate of TB disease among healthcare
58	workers is estimated to be at least double that of the general adult population, suggesting significant
59	transmission in health facilities(8,9). The FAST (Find cases Actively, Separate safely, and Treat
60	effectively) strategy was developed to reduce TB transmission in healthcare settings, based on the
61	principle that most transmission occurs from patients with unsuspected and thus undiagnosed TB,
62	including drug-resistant strains(10). FAST relies on identifying potentially infectious patients, typically
63	with cough screening, followed by rapid sputum-based molecular tests that include first line
64	resistance testing to enable prompt initiation of effective treatment(7,10). FAST has been
65	implemented in a variety of settings, including Peru, Bangladesh, Russia, and Vietnam(11–14). Given
66	the slow scale up of rapid molecular tests(1), due to barriers such as cost, optimizing screening
67	approaches for the FAST strategy is critical for its implementation success.
68	

Triage is the process of making clinical decisions based on symptoms, signs, risk factors, or test results(15). Rapid and accurate triage tests play an important role in identifying patients requiring further diagnostic evaluation among those with symptoms or risk factors for disease(16). Screening similarly involves non-diagnostic testing to distinguish between people who likely have the disease from those who are unlikely to have the disease, typically in a population who do not have symptoms(15). There is a long history of using chest radiography (CXR) to screen for pulmonary TB,

75	but its utility in high TB incidence settings has been limited by the scarcity of skilled radiologists to
76	interpret images(17). The advent of digital radiography coupled with computer aided detection (CAD)
77	software eliminates this potential barrier, making it more feasible to implement CXR for triage or
78	screening in resource limited settings. CAD uses artificial intelligence algorithms to analyze
79	radiographs for abnormalities consistent with TB. CAD is now recommended by the World Health
80	Organization (WHO) as an alternative to human readers(17). Nonetheless, while CAD sensitivity for
81	both triage and screening is typically >90%, CAD specificity varies widely, from 23%–66% for
82	screening(15,18,19) and 25%–79% for triage(18,20) when compared to a microbiological reference
83	standard.
84	
85	Questions remain regarding the optimal approach for using CAD to identify potentially infectious
86	people with TB, particularly in hospital settings. A retrospective case-control study evaluating CAD in
87	patients presenting with respiratory symptoms to a tertiary care hospital in India demonstrated
88	moderate sensitivity and specificity (71% and 80% respectively) for the detection of pulmonary
89	TB(21). However, TB prevalence surveys reveal a high proportion of people diagnosed with
90	pulmonary TB who do not report symptoms(22), highlighting poor implementation and yield of
91	symptom screening(23). Moreover, many CAD studies have focused on triage of outpatients
92	presenting with symptoms(24–27). Although there are some examples of CAD screening programs
93	that are not contingent on symptom screening, these have been community-based(28–31).
94	
95	The aim of this study was to evaluate the diagnostic accuracy of digital CXR with CAD software as a

tool for: 1) triage—among patients with cough or TB risk factors—and 2) screening—among patients

- 97 without cough or TB risk factors—to identify admitted patients who should undergo molecular TB
 98 testing in a tertiary care hospital in Lima, Peru.
- 99
- 100 Methods
- 101 <u>Study design and participants</u>

102 We conducted a cross-sectional diagnostic accuracy study that was embedded in a larger prospective study evaluating FAST implementation at Hospital Nacional Hipolito Unanue (HNHU), a 700-bed 103 104 public, tertiary-care referral hospital in Lima, Peru (https://clinicaltrials.gov/ct2/show/NCT02355223). 105 Patients admitted to HNHU from January 18th 2018 to December 31st 2019 were consecutively screened by the FAST implementation team study staff using a standardized questionnaire upon 106 107 facility admission, as previously described(11). This diagnostic accuracy sub-study consisted of two 108 cohorts: triage and screening. Individuals who were eligible for the parent FAST study were eligible 109 for the triage cohort; adults (\geq 18 years old) who, upon questioning by the study team, reported 110 either cough of any duration and/or the following risk factors for TB: contact with someone 111 diagnosed with pulmonary TB, a current active TB diagnosis (however patients who were already on 112 TB treatment were subsequently excluded from this diagnostic accuracy sub-study), or a history of prior active TB. The screening cohort consisted of individuals who were assessed for eligibility for the 113 114 parent FAST study but were ineligible because they did not have cough or TB risk factors. The 115 rationale for adding a screening cohort to the diagnostic accuracy sub-study was to see the number of patients admitted in our setting in Lima without identified TB risk who may have undiagnosed TB 116 117 (based on prevalence survey data from other higher TB incidence settings)(22). Every one in five patients with a negative symptom or TB risk screen (undertaken by our FAST implementation study 118

team) was randomly approached for enrollment into the screening cohort for this diagnostic sub-

120 study.

121

|--|

- 123 The study was approved by the Institutional Review Boards of HNHU and Brigham and Women's
- 124 Hospital. Written informed consent was obtained from all patients. Participants were assigned a
- 125 unique study ID number, recorded on data collection forms and clinical specimens to facilitate data
- 126 linkage; names and other obvious identifiers were not used on data collection forms thus authors did
- 127 not have access to information that could identify individual participants during or after data
- 128 collection.
- 129

130 <u>Study procedures, data collection, and outcome classification</u>

131 On the day of admission, patients in both cohorts who were admitted through the emergency room 132 underwent posterior-anterior digital CXR and study staff collected at least 2 sputum samples for TB 133 testing using smear microscopy, mycobacterial culture, Xpert MTB/RIF (Xpert, Cepheid, Sunnyvale, CA), and/or GenoType MTBDRplus line probe assay (Hain, Germany). De-identified CXR images were 134 135 electronically transferred for automated analysis and were blinded to other demographic and clinical 136 data including the results of other TB testing by the developers of qXR (qure.ai, Mumbai, India) who 137 ran versions 3.0 (v3) and 4.0 (v4) on all images. CXR was obtained prospectively but qXR results were not used to guide clinical management. Information on socio-demographic and clinical variables 138 139 including current and prior TB history, co-morbidities, and microbiological test results, was collected at the time of enrollment, or retrieved from the medical records using standardized case report 140 141 forms. Culture and Xpert results were classified separately as binary variables (positive or negative for

Mycobacterium tuberculosis). If a patient had more than one culture result and at least one was
positive, the binary result was classified as positive and the same applied to Xpert results.

144

145 <u>Analyses</u>

For our primary diagnostic accuracy analyses, the diagnosis of pulmonary TB in both the triage and 146 147 screening cohorts was established by the presence of a sputum culture that grew *Mycobacterium* 148 tuberculosis. For our secondary diagnostic accuracy analyses, the diagnosis of pulmonary TB in both 149 the triage and screening cohorts was established by the presence of a positive sputum Xpert result. 150 Analyses using qXR v4 are presented in the main manuscript and qXR v3 are presented in the 151 supplementary data. gXR sensitivity and specificity (with exact 95% C.I.s) for pulmonary TB were 152 calculated using the manufacturer's prespecified thresholds (0.5 for v3 and v4) per STARD guidelines 153 (see Appendix for STARD checklist)(32). DeLong's non-parametric method was applied to compare 154 differences between the areas under the receiver operating characteristic curve (AUC) for the two 155 gXR software versions. We also estimated the specificity at the threshold score at which sensitivity 156 was closest to 90% (WHO triage test minimum TPP recommended criteria)(33). Pre-specified 157 sensitivity analyses were designed to examine qXR accuracy when certain groups known to have increased risk for TB were excluded: people with HIV, people with prior TB, and people with other 158 159 respiratory diseases (asthma or bronchiectasis).

160

Using Fisher's exact test, we assessed performance differences in prespecified groups with
 characteristics or risk factors that may impact diagnostic test performance: male sex, older age, prior
 TB, HIV co-infection, other respiratory disease co-morbidities, presence of TB symptoms in WHO
 symptom screen (cough, fever, night sweats, weight loss), and higher-grade sputum smear result.

- 165 Analyses were completed using STATA/IC version 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.). 166 167 Results 168 During the study period we enrolled 1006 patients admitted to HNHU who had cough or TB risk 169 factors, of whom 489 underwent digital CXR in the triage cohort (Figure 1). Participants who were 170 taking TB treatment or had been on TB treatment within one year of enrollment (n=50; 10%) were 171 172 excluded as were those who had no microbiological testing (n=20; 4%). We enrolled 220 individuals 173 without cough or TB risk factors in the screening cohort. Screening participants who were household contacts of people who experienced TB were excluded (n=27; 13%) as were those who had no 174 175 microbiological testing (n=9; 4%). 176 177 Figure 1: Study Flow Diagram 178 179 Triage cohort 180 181 Demographics 182 Of the 419 participants in the triage cohort, 387 (93%) had a mycobacterial culture result that was positive in 65 (17%) participants, of whom 41 (63%) also had positive sputum-smear microscopy 183 184 results. In this cohort, 398 (95%) had an Xpert MTB/RIF result; it was positive in 69 (17%), of whom 39
- 185 (57%) had positive smear microscopy. Culture and Xpert results were largely concordant, with high
- 186 Xpert sensitivity for both smear-positive and negative culture confirmed TB (95% and 86%), although
- 187 Xpert was positive in some people who did not have culture or who had a negative culture (Table S1a
- and b). Compared to participants without TB (based on sputum culture results), participants with

- culture confirmed TB were more likely to be younger, male, have a history of incarceration, report cough longer than 2 weeks, fever, or weight loss, and not have a history of any respiratory diseases or a prior history of TB (Table 1). The primary reason for excluding patients from the triage cohort was that they were not admitted through the emergency department (n=397/517), which was required for us to be able to obtain dCXR. Differences between included versus excluded patients are
- 194 described in Table S2.
- 195
- 196 Table 1: Demographic and clinical characteristics of enrolled participants

			Triage P	Screening* P	Screening* Patients		
	Overall (n=419)	TB^	No TB	No Culture	P-	Overall	P-
		(n=65)	(n=322)	Performed	value**	(n=184)	value**
				(n=32)			
Median Age (years,	41.35 (26.8, 56.6)	35.34	42.01	44.68 (31.7,	0.003	36.19 (25.19,	0.015
interquartile range)		(24.0,	(27.5,	63.3)		50.53)	
		48.6)	57.0)				
Sex, No (%)							
Female	164 (39.1)	17 (26.1)	134 (41.6)	13 (40.6)	0.025	111 (60.3)	<0.001
Male	255 (60.9)	48 (73.9)	188 (58.4)	19 (59.4)		73 (39.7)	
History of Previous TB,							
No (%)							
Yes	140 (33.4)	13 (20.0)	114 (35.4)	13 (40.6)	0.014	0 (0.00)	<0.001
No	278 (66.4)	52 (80.0)	207 (64.3)	19 (59.4)		184 (100)	
Refused	1 (0.20)	0 (0.00)	1 (0.3)	0 (0.00)		0 (0.00)	
HIV, No (%)							
Yes	36 (8.6)	7 (10.8)	28 (8.7)	1 (3.1)	0.635	1 (0.5)	<0.001
No	383 (91.4)	58 (89.2)	294 (91.3)	31 (96.9)		183 (99.5)	
Smoking, No (%)							
Never	202 (48.2)	28 (43.0)	162 (50.3)	12 (37.5)	0.501	99 (53.8)	0.637
Former	161 (38.4)	30 (46.2)	116 (36.0)	15 (46.9)		51 (27.7)	
Current	56 (13.4)	7 (10.8)	44 (13.7)	5 (15.6)		34 (18.5)	
Alcohol, No (%)							
Never	107 (25.5)	9 (13.9)	90 (28.0)	8 (25.0)	0.092	32 (17.3)	<0.001
Former	121 (28.9)	22 (33.9)	90 (28.0)	9 (28.1)		33 (18.0)	
Current	189 (45.1)	32 (49.2)	142 (44.0)	15 (46.9)		119 (64.7)	
Missing	2 (0.5)	2 (3.0)	0 (0.00)	0 (0.00)		0 (0.00)	
Respiratory Disease, No							
(%)							
Asthma	28 (6.7)	1 (1.5)	26 (8.1)	2 (6.3)	0.047	2 (1.1)	0.001
Bronchiectasis	13 (3.1)	0 (0.00)	11 (3.4)	1 (3.1)		0 (0.00)	
None	378 (90.2)	64 (98.5)	285 (88.5)	29 (90.6)		182 (98.9)	
Diabetes, Type II, No							
(%)				- ()			
Yes	58 (13.8)	9 (13.9)	42 (13.0)	/ (21.9)	0.842	25 (13.6)	1.000

No	361 (86.2)	56 (86.1)	280 (87.0)	25 (78.1)		159 (86.4)	
Prison, No (%)							
Yes	62 (14.8)	16 (24.6)	41 (12.7)	5 (15.6)	0.020	3 (1.6)	<0.001
No	357 (85.2)	49 (75.4)	281 (87.3)	27 (84.4)		181 (98.4)	
Household Contact of						(
TB positive patient. No							
(%)							
Yes	159 (38.0)	27 (41 5)	119 (37 0)	13 (40.6)	0 754	_	_
No	256 (61 1)	38 (58 5)	199 (61.8)	19 (59 4)	01701		
Missing	4 (0.9)	0 (0.00)	4 (1.2)	0 (0.00)			
Smear Status, No (%)	. (0.07		. (=.=)				
Positive	48 (11.5)	41 (63.1)	4 (1.2)	3 (9.4)	<0.001	0 (0.00)	<0.001
Negative	363 (86.6)	16 (24.6)	318 (98.8)	29 (90.6)		183 (99.5)	
Missing	8 (1.9)	8 (12.3)	0 (0.00)	0 (0.00)		1 (0.5)	
	0 (113)	TB-associ	ated Sympton	ms		1 (0.0)	
Cough No (%)			, .				
Length in Weeks							
Less than 1 week	102 (24.4)	8 (12.3)	90 (28.0)	4 (12.5)	0.003	_	_
1-2 weeks	107 (25 5)	16 (24-6)	81 (25 1)	10 (31 2)			
More than 2 weeks	189 (45.1)	39 (60.0)	132 (41.0)	18 (56.3)			
Missing	21 (5.0)	2 (3.1)	19 (5.9)	0 (0.00)			
1111001118	22 (010)	2 (0:1)	10 (0.0)	0 (0100)			
Phlegm							
Yes	352 (84.0)	60 (92.3)	262 (81.4)	30 (93.8)	0.056	-	-
No	47 (11.2)	3 (4.6)	42 (13.0)	2 (6.2)			
Missing	20 (4.8)	2 (3.1)	18 (5.6)	0 (0.00)			
Blood							
Yes	166 (39.6)	33 (50.8)	120 (37.3)	13 (40.6)	0.068	-	-
No	233 (55.6)	30 (46.2)	184 (57.1)	19 (59.4)			
Missing	20 (4.8)	2 (3.0)	18 (5.6)	0 (0.00)			
Fever, No (%)							
Yes	265 (63.3)	52 (80.0)	192 (59.6)	21 (65.6)	0.001	85 (46.2)	<0.001
No	153 (36.5)	12 (18.5)	130 (40.4)	11 (34.4)		99 (53.8)	
Refused	1 (0.2)	1 (1.5)	0 (0.00)	0 (0.00)		0 (0)	
Night Sweats in the last							
3 months, No (%)							
Yes	251 (59.9)	45 (69.2)	182 (56.5)	24 (75.0)	0.072	52 (28.3)	<0.001
No	168 (40.1)	20 (30.8)	140 (43.5)	8 (25.0)		132 (71.7)	
Weight Loss							
(unintentional), No (%)							
Yes	293 (69.9)	55 (84.6)	218 (67.7)	20 (62.5)	0.004	84 (45.6)	<0.001
No	123 (29.4)	9 (13.9)	102 (31.7)	12 (37.5)		98 (53.3)	
Refused	3 (0.7)	1 (1.5)	2 (0.6)	0 (0.00)		2 (1.1)	
Difficulty Breathing, No							
	335 (80.0)	51 (78 5)	260 (80.8)	24 (75 0)	0 732	52 (28 3)	<0.001
No	84 (20 0)	1/ (21 5)	62 (10 2)	8 (25 0)	0.752	132 (20.5)	~0.001
	07 (20.0)	L T (C T . J)	02 (10.2)	0 (20.0)		(///	1

197

198 ^ TB was diagnosed based on positive sputum culture i.e., pulmonary TB, we did not include clinical diagnoses
 199 or include evaluation for extra-pulmonary TB

200

201 *Screening cohort consists of patients who did not report cough or TB risk factors

202

** Fisher's exact test on binary variables, chi-square test for categorical variables, Wilcoxon rank sum test for
 continuous variables, and Jonckeere-Terpstra test for ordered categorical variables. The first p value
 represents a comparison between participants with and without pulmonary TB in the triage cohort and the
 second p value represents the comparison between the overall triage and screening cohort participant groups.
 The missing and refused categories are excluded from statistical comparisons.

208

209 <u>Diagnostic accuracy</u>

210	Using culture as the	reference standar	d for pulmonary	TB, q	XR v4 (at t	he manufacturer	pre-specified
-----	----------------------	-------------------	-----------------	-------	-------------	-----------------	---------------

- threshold of 0.5) had an overall sensitivity for pulmonary TB of 0.91 (59/65, 95% CI 0.81-0.97),
- 212 specificity of 0.32 (103/322, 95% CI 0.2731-0.37), and AUC of 0.78 (95% CI 0.72-0.84) (Table 2). Using
- 213 Xpert as the reference standard for pulmonary TB, qXR v4 (at the manufacturer pre-specified
- threshold of 0.5) had an overall sensitivity of 0.93 (64/69, 95% CI 0.84-0.98), specificity of 0.32
- 215 (106/329, 95% CI 0.27-0.38), and AUC of 0.76 (95% CI 0.69-0.82) (Table 2). Using a combined
- 216 reference standard that was positive if either culture or Xpert was positive, sensitivity and specificity
- for qXR v4 were similar (0.93 and 0.33 respectively) (Table S3). When the threshold was set such that
- sensitivity was 90% to match the WHO triage test accuracy performance criterion, specificity was 0.44
- 219 (142/322, 95% CI 0.39-0.50) and 0.38 (126/329, 95% CI 0.33-0.44) using the culture and Xpert
- reference standards respectively (Table 2). Diagnostic accuracy results for qXR v3 are in Table S5.
- 221
- Table 2: Summary of Diagnostic Accuracy for qXR version 4 using the culture (primary) and Xpert
 (secondary) reference standards in the triage and screening cohorts.

	Triage Cohort			So	reening Cohort		
		(n=419)		(n= 184)			
	Sensitivity	Specificity	AUC	Sensitivity	Specificity	AUC	
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	
			Culture				
Manufacturer	90.8%	32.0%	0.779	^	93.6%	-	
Threshold	59/65	103/322	(0.716,		161/172		
0.5	(81-96.5%)	(26.9-37.4%)	0.843)		(88.8 -96.4%)		
Threshold	90.8%	44.1%	-	^	96.5%	-	
0.7*	59/65	142/322			(166/172)		

	(81-96.5%)	(38.6-49.7%)			(92.4-98.4%)	
			Xpert			
Manufacturer	92.8%	32.2%	0.756	100%	93.9%	0.994
Threshold	64/69	106/329	(0.693 <i>,</i>	1/1	168/179	(- <i>,</i> 1.00)
0.5	(83.9-97.6%)	(27.2-37.6%)	0.819)	(2.5-100%)	(89.3-96.9%)	
Threshold	89.9%	38.3%	-	100%	96.6%	-
0.6*	62/69	126/329		1/1	173/179	
	(80.2-95.8%)	(33-43.8%)		(2.5-100%)	(92.8-98.8%)	

224

225 *threshold at which sensitivity is closest to 90%

- 226 ^No positive cultures in the Screening Group
- 227
- 228 There was no difference between the AUCs for qXR v4 and qXR v3 using either the culture reference

standard (0.779 [95% CI 0.72-0.84] versus 0.780 [95% CI 0.72-0.84; p=0.821]) or the Xpert reference

230 standard (0.756 [95% CI 0.69-0.82] versus 0.759 [95% CI 0.70-0.82]; p=0.475) (Figure 2).

231

Figure 2: Receiver operating characteristic (ROC) curves and estimates of area under the ROC curves (AUC) for qXR versions 3 and 4 to identify abnormalities consistent with TB in the triage cohort using the culture (left) and Xpert (right) reference standards.

235

236 <u>Stratified analyses</u>

237 There was no difference in qXR v4 sensitivity when stratified by sex, age, prior TB, HIV, and symptoms

238 (Figure 3). qXR v4 specificity was higher in people without prior TB than in people with prior TB, with

cough less than 2 weeks compared to cough for more than 2 weeks, and with those who did not

- report weight loss compared to those who reported weight loss (Figure 4). Similarly, qXR v4
- sensitivity appeared to be higher in smear-positive compared to smear-negative disease but did not
- reach statistical significance and numbers of participants with smear negative disease were low.
- 243
- 244

Figure 3: Sensitivity of qXR version 4 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests.

247

Figure 4: Specificity of qXR version 4 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests.

250

251 <u>Sensitivity analyses</u>

252 We examined qXR accuracy when pre-specified groups in whom TB diagnostic tests are often less

253 sensitive (PWH, people with prior TB and people with other respiratory diseases) were excluded.

254 Sensitivity for qXR v4 was slightly higher in people without HIV (0.93 [95% CI: 0.83-0.98]), slightly

lower in people without prior TB (0.89 [95% CI: 0.77-0.96]), and similar in people without other

respiratory diseases (0.91 [95% CI: 0.81-0.97]). Specificity remained low in people without HIV: 0.31

257 [95% CI: 0.25-0.36] and people without other respiratory diseases: 0.33 [95% CI: 0.27-0.38], and

slightly higher in people without prior TB: 0.40 [95% CI: 0.34-0.47] (Table S4).

259

260 <u>High prevalence of lung abnormalities</u>

A high prevalence of radiographic lung abnormalities, most notably opacities (81%), consolidation

262 (62%), fibrosis (47%), nodules (58%), or cavitation (19%), was detected by qXR on digital CXR images

263 from the triage cohort (Table S6).

264

265 Screening cohort

266 Compared to participants in the triage cohort, participants in the screening cohort were more likely 267 to be younger and female, not have a history of HIV, any respiratory diseases or a prior history of TB, 268 not have a history of incarceration, more likely to report current alcohol use, and less likely to report 269 fever, night sweats, or weight loss (Table 1). No participants in the screening cohort had a positive

270	culture, and only one participant had a positive Xpert. Since there was only one person with
271	confirmed TB in the screening group (who did have a qXR positive result), we only report specificity.
272	Using the manufacturer's pre-specified thresholds, the specificity for qXR v4 was 0.94 (95% CI 0.89-
273	0.96) using the culture reference standard and 0.94 (95% CI 0.89-0.97) using the Xpert reference
274	standard (Table 2).
275	
276	Discussion
277	In our study population of hospitalized patients at a tertiary referral hospital in Lima, Peru, the use of
278	qXR artificial intelligence software analysis versions 3 and 4 in a triage cohort of patients with cough
279	or TB risk factors demonstrated a high sensitivity (>90%) but low specificity (~30%), thereby meeting
280	only the WHO triage test criteria for sensitivity. In our screening cohort of patients without cough or
281	risk factors, specificity was high (>90%) but sensitivity could not be evaluated since the diagnostic
282	yield of screening this group in this setting was low (only one patient was diagnosed with Xpert-
283	positive TB).
284	
285	We previously reported that the FAST strategy using Xpert for molecular diagnosis increased the yield
286	of TB diagnosis and decreased time to treatment initiation(11). Yet, despite WHO guidance that
287	molecular WHO-recommended rapid TB diagnostic tests (mWRD) such as Xpert should be the initial
288	test for people being evaluated for TB, implementation in Peru and other high-incidence settings has
289	lagged(1). While barriers to mWRD implementation are multifactorial(34), cost and limited laboratory
290	capacity were challenges to the implementation of Xpert as a triage or screening test as part of
291	routine practice in our setting. The use of a triage tool such as digital CXR with CAD can help identify
292	which patients should undergo testing with a mWRD(16) as part of transmission prevention strategies

293 such as FAST. In our hospitalized study population, gXR was highly sensitive for correctly triaging 294 people identified as having cough or TB risk factors who had culture confirmed disease. Although low 295 qXR specificity would lead to a large number of patients with false positive results who required 296 confirmatory testing and widespread use of digital CXR with CAD poses implementation challenges. 297 gXR as a triage tool could be of clinical and public health value due to its impact on diagnostic yield 298 and may still save enough mWRDs to be cost-effective depending on the setting (cost-effectiveness 299 analyses from our study are forthcoming). When we adjusted the threshold for gXR v4 to maintain 300 sensitivity at 90%, specificity rose to 38-44%; thus our data add further weight to the need for 301 population-specific thresholds(35) to optimize implementation of CAD tools in different settings. 302 303 The low specificity of qXR in inpatients with TB symptoms or risk factors contrasts with cross-304 sectional studies that found that gXR met WHO triage test criteria for both sensitivity (>90%) and 305 specificity (70%) when evaluated in symptomatic outpatients in Bangladesh and Pakistan(24) (36). 306 Our triage cohort had a high prevalence of radiographic lung abnormalities, which was likely to be an 307 important contributing factor to the lower than expected specificity in this cohort. Abnormal chest 308 imaging findings in our study population may be due to inpatient populations in a tertiary referral 309 hospital being more likely to have acute illnesses such as pneumonia, and may also reflect a higher 310 proportion of people with chronic lung disease in Lima, a city known to have high rates of air

pollution, which has also been associated with a higher risk of tuberculosis(37). We also note that

this diagnostic accuracy assessment in the triage cohort reflects use of the test in a pre-screened

313 population who had a high pre-test probability of TB or other lung disease and underwent

314 microbiological testing that revealed a high prevalence of TB. Thus, negative predictive value would

be lower for this cohort than if qXR testing was applied to the population of people initially screened(rather than those enrolled) for FAST.

317

318	Increasing data demonstrate symptom screening is insensitive(38) and often poorly
319	implemented(39), and a high proportion of people with TB do not report symptoms(22). The inclusion
320	of individuals without cough or risk factors in our screening cohort was designed to try to understand
321	the potential diagnostic yield of using qXR as a screening tool to identify unsuspected TB in
322	hospitalized patients who may be presenting for various other reasons. In this setting, the diagnostic
323	yield of screening people without symptoms or risk factors was lower than expected (based on
324	outpatient studies). The specificity of qXR was high, suggesting it could be a valuable rule-out test in
325	this setting. The low prevalence of TB in the screening cohort may be an artifact of the sample size or,
326	it may be because people with TB who present to hospital are more likely to be sicker due to TB and
327	thus present with cough (resulting in exclusion from the screening cohort) compared to the
328	outpatient populations in prevalence surveys. The exclusion of people with TB contacts and prior TB
329	from the screening cohort may have also led to the screening cohort being a lower risk group. The
330	implementation of strategies such as FAST should consider local epidemiologyincluding the pre-test
331	probability of TB in people who do not report symptoms—to determine the optimal approach to
332	determining who should undergo mWRD testing. Other strategies could also be evaluated to increase
333	the sensitivity of screening.

334

Strengths of our study include generating CAD diagnostic accuracy data from inpatient populations,
including those who were symptomatic and/or high-risk and those without identified cough or TB risk
factors, also contributing to a body of literature seeking to optimize the FAST facility-based

338 transmission prevention strategy in a medium incidence setting. We provide the first head-to-head 339 evaluation of version 4 (soon to be commercially available) compared to gXR version 3 and 340 characterize other lung abnormalities detected. We acknowledge the challenges posed by imperfect reference standards for TB diagnostic accuracy studies (16), although we suspect that paucibacillary 341 disease (which could cause culture, Xpert, and also CXR to be negative) is less likely in a hospitalized 342 343 cohort in a low-HIV prevalence setting. Moreover, the inclusion of reference standard data from 344 both mycobacterial culture and Xpert is a strength since many diagnostic studies only use Xpert as 345 the refence standard. Limitations of our study are that digital CXR could only be performed on 346 inpatients admitted through the emergency room (which may bias the study towards sicker hospitalized patients) and that with only 65 patients who had culture-confirmed TB, the study only 347 348 had sufficient power such that we can report the lower limit of the 95% CI for sensitivity is 0.885 with 349 95% precision. We note low numbers in certain subgroups, including the number with HIV due to the 350 low incidence of HIV in Peru and number with smear negative disease, also limit the power to detect 351 differences in our stratified analyses. 352

In conclusion, qXR had high sensitivity but low specificity as a triage tool in the context of use within the FAST strategy in hospitalized adults admitted to a tertiary referral hospital in Peru who had a high prevalence of other radiographic lung abnormalities. While specificity was high in patients without cough or risk factors, the diagnostic yield of screening these patients was low in this setting. These findings further support the need for population and setting-specific thresholds for CAD programs and provide additional insights into the role for triage testing in hospitalized patients, which remains critical to detect and treat individual patients earlier and to curb hospital TB transmission.

360

- **361** Supporting information captions:
- 363 Table S1a: Summary of Culture and Xpert results concordance.
- Table S1b: Xpert sensitivity for smear-positive and smear-negative culture-positive TB in triage cohortpatients
- Table S2: Demographic and clinical characteristics of enrolled participants compared to those whowere excluded.
- 369

372

375

366

362

- Table S3: Diagnostic accuracy of qXR Version 3 and 4 using a reference standard which is positive if either mycobacterial culture or Xpert is positive for the triage cohort.
- Table S4: Diagnostic accuracy of qXR Version 3 and 4 for pre-specified subgroups in the triage cohort for which participants with prior TB, respiratory diseases, and HIV, were excluded
- Table S5: Summary of Diagnostic Accuracy for qXR version 4 compared to the culture (primary) and
 Xpert (secondary) reference standards
- 378
- Table S6: Lung abnormalities detected by qXR analysis for the Triage and Screening cohorts
- Figure S1: Sensitivity of qXR version 3 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests.
- 383

380

Figure S2: Specificity of qXR version 3 for culture-confirmed pulmonary tuberculosis, overall and in
 prespecified stratified groups. p values are from Fisher's exact tests.

Acknowledgements

The authors were allowed to use the qXR algorithms free of charge from qure.ai for research purposes, but the companies had no influence over the research question, nor any other aspect of the work carried out, and had no impact on the transparency of the article.

Funding

This work was funded by the National Institutes of Health (NIAID R01 AI112748, PIs: Nardell and Tierney, and NIAID K23 AI132648-05, PI: Nathavitharana). RRN also acknowledges support from an American Society of Tropical Medicine and Hygiene Burroughs Wellcome Fellowship.

The funders had no role in study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication. The content is solely the responsibility of the authors and does not necessarily represent the views of the funders.

Competing interests

The authors declare that no competing interests exist.

Data Availability Statement

All relevant data are uploaded to the Harvard Dataverse repository.

References

- World Health Organization. Global tuberculosis report 2022 [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Dec 5]. Available from: https://apps.who.int/iris/handle/10665/363752
- 2. Subbaraman R, Jhaveri T, Nathavitharana RR. Closing gaps in the tuberculosis care cascade: an action-oriented research agenda. J Clin Tuberc Other Mycobact Dis. 2020/02/20 ed. 2020 May;19:100144.
- 3. Willingham FF, Schmitz TL, Contreras M, Kalangi SE, Vivar AM, Caviedes L, et al. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. Emerg Infect Dis. 2001/03/27 ed. 2001 Jan;7(1):123–7.
- 4. Assefa D, Belachew F, Wondimagegn G, Klinkenberg E. Missed pulmonary tuberculosis: a cross sectional study in the general medical inpatient wards of a large referral hospital in Ethiopia. BMC Infect Dis. 2019/01/19 ed. 2019 Jan 17;19(1):60.
- 5. Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis. 2012/11/21 ed. 2013 Jan 1;207(1):9–17.
- Migliori GB, Nardell E, Yedilbayev A, D'Ambrosio L, Centis R, Tadolini M, et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J [Internet]. 2019/04/27 ed. 2019 Jun;53(6). Available from: https://www.ncbi.nlm.nih.gov/pubmed/31023852
- 7. Nardell EA. Transmission and Institutional Infection Control of Tuberculosis. Cold Spring Harb Perspect Med. 2015/08/22 ed. 2015 Aug 20;6(2):a018192.
- 8. World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Jun 6] p. 6. Available from: https://apps.who.int/iris/handle/10665/353743
- 9. Paleckyte A, Dissanayake O, Mpagama S, Lipman MC, McHugh TD. Reducing the risk of tuberculosis transmission for HCWs in high incidence settings. Antimicrob Resist Infect Control. 2021/07/21 ed. 2021 Jul 19;10(1):106.
- 10. Barrera E, Livchits V, Nardell E. F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy. Int J Tuberc Lung Dis. 2015/04/11 ed. 2015 Apr;19(4):381–4.
- 11. Tierney DB, Orvis E, Nathavitharana RR, Hurwitz S, Tintaya K, Vargas D, et al. FAST tuberculosis transmission control strategy speeds the start of tuberculosis treatment at a general hospital in Lima, Peru. Infect Control Hosp Epidemiol. 2021 Oct 6;1–7.

- 12. Nathavitharana RR, Daru P, Barrera AE, Mostofa Kamal SM, Islam S, Ul-Alam M, et al. FAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up. Int J Tuberc Lung Dis. 2017/08/23 ed. 2017 Sep 1;21(9):1020–5.
- 13. Miller AC, Livchits V, Ahmad Khan F, Atwood S, Kornienko S, Kononenko Y, et al. Turning Off the Tap: Using the FAST Approach to Stop the Spread of Drug-Resistant Tuberculosis in the Russian Federation. The Journal of Infectious Diseases. 2018 Jul 13;218(4):654–8.
- 14. Le H, Nguyen N, Tran P, Hoa N, Hung N, Moran A, et al. Process measure of FAST tuberculosis infection control demonstrates delay in likely effective treatment. Int J Tuberc Lung Dis. 2019/01/10 ed. 2019 Feb 1;23(2):140–6.
- WHO. WHO Consolidated guidelines on tuberculosis, Module 2: Screening, Systematic screening for tuberculosis disease [Internet]. WHO; 2021. Available from: https://reliefweb.int/report/world/who-consolidated-guidelines-tuberculosis-module-2screening-systematic-screening
- 16. Nathavitharana RR, Yoon C, Macpherson P, Dowdy DW, Cattamanchi A, Somoskovi A, et al. Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. The Journal of Infectious Diseases. 2019 Oct 8;220(Supplement_3):S116–25.
- 17. WHO. CHEST RADIOGRAPHY IN TUBERCULOSIS DETECTION [Internet]. WHO; 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/252424/9789241511506-eng.pdf
- 18. Kik SV, Gelaw SM, Ruhwald M, Song R, Khan FA, van Hest R, et al. Diagnostic accuracy of chest X-ray interpretation for tuberculosis by three artificial intelligence-based software in a screening use-case: an individual patient meta-analysis of global data [Internet]. Infectious Diseases (except HIV/AIDS); 2022 Jan [cited 2022 Dec 5]. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.01.24.22269730
- 19. Gelaw SM, Kik SV, Ruhwald M, Ongarello S, Egzertegegne TS, Gorbacheva O, et al. Diagnostic accuracy of three computer-aided detection systems for detecting pulmonary tuberculosis on chest radiography when used for screening: analysis of an international, multicenter migrants screening study [Internet]. Radiology and Imaging; 2022 Apr [cited 2022 Dec 5]. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.03.30.22273191
- 20. Tavaziva G, Harris M, Abidi SK, Geric C, Breuninger M, Dheda K, et al. Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy. Clinical Infectious Diseases. 2021 Jul 21;ciab639.
- 21. Nash M, Kadavigere R, Andrade J, Sukumar CA, Chawla K, Shenoy VP, et al. Deep learning, computer-aided radiography reading for tuberculosis: a diagnostic accuracy study from a tertiary hospital in India. Sci Rep. 2020 Dec; 10(1):210.
- Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical Tuberculosis Disease—A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. Clinical Infectious Diseases. 2021 Aug 2;73(3):e830–41.

- 23. Divala TH, Lewis J, Bulterys MA, Lutje V, Corbett EL, Schumacher SG, et al. Missed opportunities for diagnosis and treatment in patients with TB symptoms: a systematic review. public health action. 2022 Mar 21;12(1):10–7.
- 24. Qin ZZ, Ahmed S, Sarker MS, Paul K, Adel ASS, Naheyan T, et al. Tuberculosis detection from chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation of five artificial intelligence algorithms. The Lancet Digital Health. 2021 Sep;3(9):e543–54.
- 25. Muyoyeta M, Maduskar P, Moyo M, Kasese N, Milimo D, Spooner R, et al. The Sensitivity and Specificity of Using a Computer Aided Diagnosis Program for Automatically Scoring Chest X-Rays of Presumptive TB Patients Compared with Xpert MTB/RIF in Lusaka Zambia. Wilkinson RJ, editor. PLoS ONE. 2014 Apr 4;9(4):e93757.
- 26. Breuninger M, van Ginneken B, Philipsen RHHM, Mhimbira F, Hella JJ, Lwilla F, et al. Diagnostic Accuracy of Computer-Aided Detection of Pulmonary Tuberculosis in Chest Radiographs: A Validation Study from Sub-Saharan Africa. Hoshino Y, editor. PLoS ONE. 2014 Sep 5;9(9):e106381.
- 27. Melendez J, Sánchez CI, Philipsen RHHM, Maduskar P, Dawson R, Theron G, et al. An automated tuberculosis screening strategy combining X-ray-based computer-aided detection and clinical information. Sci Rep. 2016 Jul;6(1):25265.
- 28. Yuen CM, Puma D, Millones AK, Galea JT, Tzelios C, Calderon RI, et al. Identifying barriers and facilitators to implementation of community-based tuberculosis active case finding with mobile X-ray units in Lima, Peru: a RE-AIM evaluation. BMJ Open. 2021 Jul;11(7):e050314.
- 29. Nguyen LH, Codlin AJ, Vo LNQ, Dao T, Tran D, Forse RJ, et al. An Evaluation of Programmatic Community-Based Chest X-ray Screening for Tuberculosis in Ho Chi Minh City, Vietnam. TropicalMed. 2020 Dec 10;5(4):185.
- 30. Madhani F, Maniar RA, Burfat A, Ahmed M, Farooq S, Sabir A, et al. Automated chest radiography and mass systematic screening for tuberculosis. int j tuberc lung dis. 2020 Jul 1;24(7):665–73.
- Mungai B, Ong'angò J, Ku CC, Henrion MYR, Morton B, Joekes E, et al. Accuracy of computeraided chest X-ray in community-based tuberculosis screening: Lessons from the 2016 Kenya National Tuberculosis Prevalence Survey. Majumdar S, editor. PLOS Glob Public Health. 2022 Nov 23;2(11):e0001272.
- 32. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015 Oct 28;h5527.
- 33. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, Switzerland; 2014 Apr.
- 34. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016 Aug;48(2):516–25.

- 35. Qin ZZ, Sander MS, Rai B, Titahong CN, Sudrungrot S, Laah SN, et al. Using artificial intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of the diagnostic accuracy of three deep learning systems. Sci Rep. 2019 Dec;9(1):15000.
- 36. Khan FA, Majidulla A, Tavaziva G, Nazish A, Abidi SK, Benedetti A, et al. Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease. The Lancet Digital Health. 2020 Nov;2(11):e573–81.
- 37. Lin YJ, Lin HC, Yang YF, Chen CY, Ling MP, Chen SC, et al. Association Between Ambient Air Pollution and Elevated Risk of Tuberculosis Development. IDR. 2019 Dec;Volume 12:3835–47.
- 38. Yoon C, Dowdy DW, Esmail H, MacPherson P, Schumacher SG. Screening for tuberculosis: time to move beyond symptoms. The Lancet Respiratory Medicine. 2019 Mar;7(3):202–4.
- Divala TH, Lewis J, Bulterys MA, Lutje V, Corbett EL, Schumacher SG. Missed opportunities for diagnosis and treatment in patients with TB symptoms: a systematic review. Public Health Action. :8.

Figure 1: Study Flow Diagram





Category and			Sensitivity
Variable	n/N	p-value	(95% CI)
Demographics			
Male	44/48	1.000	→ 0.92 (0.80, 0.98)
Female	15/17		0.88 (0.64, 0.98)
<40 years	35/38	1.000	→ 0.92 (0.79, 0.98)
>40 years	24/27		••• 0.89 (0.71, 0.98)
Risk Factors			
No Prior TB	46/52	0.828	0.89 (0.77, 0.99)
Prior TB	13/13		1.00 (0.75, 1.00)
HIV Negative	54/58	0.766	→ 0.93 (0.83, 0.98)
HIV Positive	5/7		0.71 (0.29, 0.96)
No Alcohol Use	8/9	1.000	→ 0.89 (0.52, 1.00)
Any Alcohol Use	49/54		→ 0.91 (0.80, 0.97)
Diabetes Negative	51/56	1.000	→ 0.91 (0.80, 0.97)
Diabetes Positive	8/9		• 0.89 (0.52, 1.00)
Clinical Symptoms			
Cough > 2 weeks	37/39	0.850	→ 0.95 (0.83, 0.99)
Cough < 2 weeks	20/24		0.83 (0.63, 0.95)
Night sweats	39/45	0.848	0.87 (0.73, 0.95)
No Night sweats	20/20		→ 1.00 (0.83, 1.00)
Fever	46/52	0.823	0.89 (0.77, 0.96)
No Fever	12/12		→ 1.00 (0.73, 1.00)
Weight Loss	49/55	1.000	0.89 (0.78, 0.96)
No Weight Loss	9/9		→ 1.00 (0.66, 1.00)
Test Results			
Smear Positive	38/41	0.830	— 0.93 (0.80, 0.98)
Smear Negative	13/16		0.81 (0.54, 0.96)
Overall			
Overall	59/65		→ 0.91 (0.81, 0.96)
		0	1 1 1 1 1 .2 .4 .6 .8 1

Category and				Specificity
Variable	n/N	p-value		(95% CI)
Demographics				
Male	49/188	0.068	—	0.26 (0.20, 0.33)
Female	54/134		_	0.40 (0.32, 0.49)
<40 years	52/150	0.499		0.35 (0.27, 0.43)
>40 years	51/172		-	0.30 (0.23, 0.37)
Risk Factors				
No Prior TB	84/207	0.001	-	0.41 (0.34, 0.48)
Prior TB	19/114			0.17 (0.10, 0.25)
HIV Negative	90/294	0.252	-	0.31 (0.25, 0.36)
HIV Positive	13/28			0.46 (0.28, 0.66)
No Alcohol Use	25/90	0.525	—	0.28 (0.19, 0.38)
Any Alcohol Use	78/232		-	0.34 (0.28, 0.40)
Diabetes Negative	88/280	0.740	—	0.31 (0.26, 0.37)
Diabetes Positive	15/42		_	0.36 (0.22, 0.52)
Clinical Symptoms				
Cough > 2 weeks	24/132	0.001	—	0.18 (0.12, 0.26)
Cough < 2 weeks	73/171		-	0.43 (0.35, 0.51)
Night sweats	56/182	0.733		0.31 (0.24, 0.38)
No Night sweats	47/140			0.34 (0.26, 0.42)
Fever	57/192	0.491		0.30 (0.23, 0.37)
No Fever	46/130			0.35 (0.27, 0.44)
Weight Loss	57/218	0.024	—	0.26 (0.20, 0.33)
No Weight Loss	46/102		-	0.45 (0.35, 0.55)
Overall				
Overall	103/322		+	0.32 (0.27, 0.38)
		1		